In vitro studies of 7-dehydrocholesterol reductase (DHCR7) activity
Ladataan...
suljettu
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
Pysyvä osoite
Verkkojulkaisu
DOI
Tiivistelmä
Cholesterol is a crucial sterol found in membranes of animal tissues. It has many important
endogenous roles, including acting as a structural component, taking part in membrane fusion,
and as a biosynthetic precursor. It is also involved in hedgehog signaling. Thus, cholesterol is
vital throughout human life.
In humans, 7-dehydrocholesterol reductase (DHCR7) forms cholesterol and desmosterol. A
malfunctioning DHCR7 may be fatal for fetuses. DHCR7 can be unintentionally inhibited by
different drugs, which may thus act as teratogens when women are exposed to them during
pregnancy. There is a limited amount of experimental information about such compounds. Thus,
screening for DHCR7 inhibition during drug development could help detect potentially
teratogenic drugs.
This study aimed to (1) characterize and assess the suitability of human hepatic subcellular
fractions for in vitro activity measurements of DHCR7, and to (2) carry out a preliminary
inhibition screening of pharmaceutical compounds, which are known/suspected DHCR7
inhibitors. For this purpose, we used commercially available hepatic subcellular fractions together
with thin-layer chromatography and liquid chromatography-tandem mass spectrometry methods.
Unexpectedly, the subcellular matrices tested contained cholesterol, making it difficult to study
the intended marker reaction. However, our data showed that the desmosterol-forming reaction
could be used for DHCR7 activity measurements. Of the tested DHCR7 inhibitors, azaperone,
mirabegron and trazodone inhibited DHCR7 when observing desmosterol levels.
In summary, we were able to demonstrate DHCR7 activity and inhibition in human liver
microsomes. However, more sensitive methods need to be developed for further analysis of
DHCR7 inhibition.